NuCana plc American Depositary Share (NCNA) is a publicly traded Healthcare sector company. As of May 21, 2026, NCNA trades at $2.00 with a market cap of $8.45M and a P/E ratio of 0.00. NCNA moved +1.77% today. Year to date, NCNA is -44.86%; over the trailing twelve months it is -78.02%. Its 52-week range spans $1.33 to $578.00. Rallies surfaces NCNA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
NuCana Gets FDA IND Clearance, Reports £21.5M Cash Runway and Q1 Net Loss: NuCana reported a £3.9 million net loss and £21.5 million cash position as of March 31, 2026, providing funding into 2029. FDA cleared IND for NUC-7738 in April 2026, and final Phase 2 data in pembrolizumab-resistant melanoma is expected later in 2026.
| Metric | Value |
|---|---|
| Price | $2.00 |
| Market Cap | $8.45M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $578.00 |
| 52-Week Low | $1.33 |
| Volume | 2.20K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
NCNA analyst coverage data. Average price target: $0.00.